The company reported very encouraging results from an early-stage study.
News & Analysis: Aptose Biosciences
Dilution is on the way.
Can the run for Sarepta Therapeutics, Viela Bio, and Aptose Biosciences continue?
APTO earnings call for the period ending March 31, 2020.
Investors weren't excited by the biotech's preliminary results from an early-stage clinical study.
Investing in this emerging cancer-focused biotech may just allow you to retire early.
Investors excited about the biotech's prospects are taking the opportunity to buy on the dip following the announcement of a new stock offering.
Promising preclinical data and the acquisition of another small biotech continued to generate enthusiasm among investors.